ebola hemorrhagic fever

Summary

Summary: A highly fatal, acute hemorrhagic fever, clinically very similar to MARBURG VIRUS DISEASE, caused by EBOLA-LIKE VIRUSES, first occurring in the Sudan and adjacent northwestern (what was then) Zaire. The natural reservoir and mode of transmission of the virus are unknown, but secondary infection is by direct contact with infected blood and other body secretions. (From Dorland, 28th ed)

Top Publications

  1. ncbi Fruit bats as reservoirs of Ebola virus
    Eric M Leroy
    Centre International de Recherches Medicales de Franceville, BP 769 Franceville, Gabon
    Nature 438:575-6. 2005
  2. pmc The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing
    A Sanchez
    Division of Viral and Ricketsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Proc Natl Acad Sci U S A 93:3602-7. 1996
  3. ncbi Multiple Ebola virus transmission events and rapid decline of central African wildlife
    Eric M Leroy
    Institut de Recherche pour le Developpement, UR034, Centre International de Recherches Medicales de Franceville, BP 769 Franceville, Gabon
    Science 303:387-90. 2004
  4. ncbi Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions
    Thomas W Geisbert
    Department of Viral Pathology and Ultrastructure, Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702 5011, USA
    Expert Rev Mol Med 6:1-24. 2004
  5. ncbi Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients
    S Baize
    Centre International de Recherches Medicales de Franceville, Gabon
    Nat Med 5:423-6. 1999
  6. pmc Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda
    Jonathan S Towner
    Special Pathogens Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
    PLoS Pathog 4:e1000212. 2008
  7. ncbi A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever
    M Bray
    Division of Virology, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702 5011, USA
    J Infect Dis 179:S248-58. 1999
  8. pmc Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection
    Thomas W Geisbert
    United States Army Medical Institute of Infectious Diseases, Fort Detrick, MD 21702 5011, USA
    Am J Pathol 163:2347-70. 2003
  9. ncbi The pathogenesis of Ebola hemorrhagic fever
    A Takada
    Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo 108 8639, Japan
    Trends Microbiol 9:506-11. 2001
  10. pmc Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome
    Jonathan S Towner
    Special Pathogens Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Virol 78:4330-41. 2004

Research Grants

  1. BORNA DISEASE VIRUS AND NEUROPSYCHIATRIC DISEASE
    WALTER LIPKIN; Fiscal Year: 2002
  2. Initiation of Nucleocapsid Assembly in Ebola virus
    SHARON CRARY; Fiscal Year: 2004
  3. Developing small molecule therapeutics for Ebola hemorrhagic fever virus
    Arnab Basu; Fiscal Year: 2010
  4. RNA Interference for the Treatment of Ebola and Marburg Hemorrhagic Fever
    Ian MacLachlan; Fiscal Year: 2010
  5. Neuronal Immunity in HIV Dementia
    HOWARD GENDELMAN; Fiscal Year: 2007
  6. HBV Prevention for Homeless At-Risk for HBV/HCV/HIV
    Adeline Nyamathi; Fiscal Year: 2007
  7. Blood Brain Barrier Physiology and HIV Dementia
    HOWARD GENDELMAN; Fiscal Year: 2007
  8. Viral Arrays for Biodefense
    W Ian Lipkin; Fiscal Year: 2007
  9. RESOURCE FOR NONHUMAN PRIMATE IMMUNE REAGENTS
    Francois Villinger; Fiscal Year: 2007
  10. RESOURCE FOR NONHUMAN PRIMATE IMMUNE REAGENTS
    Francois Villinger; Fiscal Year: 2005

Detail Information

Publications183 found, 100 shown here

  1. ncbi Fruit bats as reservoirs of Ebola virus
    Eric M Leroy
    Centre International de Recherches Medicales de Franceville, BP 769 Franceville, Gabon
    Nature 438:575-6. 2005
    ..We find evidence of asymptomatic infection by Ebola virus in three species of fruit bat, indicating that these animals may be acting as a reservoir for this deadly virus...
  2. pmc The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing
    A Sanchez
    Division of Viral and Ricketsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Proc Natl Acad Sci U S A 93:3602-7. 1996
    ..This genetic stability may indicate that EBO viruses have coevolved with their natural reservoirs and do not change appreciably in the wild...
  3. ncbi Multiple Ebola virus transmission events and rapid decline of central African wildlife
    Eric M Leroy
    Institut de Recherche pour le Developpement, UR034, Centre International de Recherches Medicales de Franceville, BP 769 Franceville, Gabon
    Science 303:387-90. 2004
    ..Surveillance of animal mortality may help to predict and prevent human Ebola outbreaks...
  4. ncbi Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions
    Thomas W Geisbert
    Department of Viral Pathology and Ultrastructure, Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702 5011, USA
    Expert Rev Mol Med 6:1-24. 2004
    ..This review summarises our current understanding of EBOV pathogenesis and discusses various approaches to therapeutic intervention based on our current understanding of how EBOV produces a lethal infection...
  5. ncbi Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients
    S Baize
    Centre International de Recherches Medicales de Franceville, Gabon
    Nat Med 5:423-6. 1999
    ..Thus, events very early in Ebola virus infection determine the control of viral replication and recovery or catastrophic illness and death...
  6. pmc Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda
    Jonathan S Towner
    Special Pathogens Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
    PLoS Pathog 4:e1000212. 2008
    ....
  7. ncbi A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever
    M Bray
    Division of Virology, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702 5011, USA
    J Infect Dis 179:S248-58. 1999
    ..Mice injected peripherally with mouse-adapted or intraperitoneally with non-adapted EBO-Z virus resisted subsequent challenge with mouse-adapted virus...
  8. pmc Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection
    Thomas W Geisbert
    United States Army Medical Institute of Infectious Diseases, Fort Detrick, MD 21702 5011, USA
    Am J Pathol 163:2347-70. 2003
    ..The sequence of pathogenetic events identified in this study should provide new targets for rational prophylactic and chemotherapeutic interventions...
  9. ncbi The pathogenesis of Ebola hemorrhagic fever
    A Takada
    Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo 108 8639, Japan
    Trends Microbiol 9:506-11. 2001
    ....
  10. pmc Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome
    Jonathan S Towner
    Special Pathogens Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Virol 78:4330-41. 2004
    The largest outbreak on record of Ebola hemorrhagic fever (EHF) occurred in Uganda from August 2000 to January 2001. The outbreak was centered in the Gulu district of northern Uganda, with secondary transmission to other districts...
  11. ncbi Laboratory diagnosis of Ebola hemorrhagic fever during an outbreak in Yambio, Sudan, 2004
    Clayton O Onyango
    World Health Organization Collaborating Center for Arbovirus and Viral Hemorrhagic Fever Reference and Research, Nairobi, Kenya
    J Infect Dis 196:S193-8. 2007
    Between the months of April and June 2004, an Ebola hemorrhagic fever (EHF) outbreak was reported in Yambio county, southern Sudan...
  12. ncbi A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever
    M Bray
    Division of Virology, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702 5011, USA
    J Infect Dis 178:651-61. 1998
    ..Mice injected peripherally with mouse-adapted or intraperitoneally with non-adapted EBO-Z virus resisted subsequent challenge with mouse-adapted virus...
  13. ncbi Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury
    Z Y Yang
    Vaccine Research Center, National Institutes of Health, 40 Convent Drive, Bethesda, Maryland 20892 3005, USA
    Nat Med 6:886-9. 2000
    ..These findings indicate that GP, through its mucin domain, is the viral determinant of Ebola pathogenicity and likely contributes to hemorrhage during infection...
  14. ncbi Defense against filoviruses used as biological weapons
    Mike Bray
    Medical Officer, Biodefense Clinical Research Branch, OCR OD NIAID NIH, 6700A Rockledge Drive, Room 5132, Bethesda, MD 20892, USA
    Antiviral Res 57:53-60. 2003
    ..Terrorists might have great difficulty acquiring a filovirus for use as a weapon, but my attempt to do so because of the agents' ability to inspire fear. Accurate information is the best tool to prevent panic in the event of an attack...
  15. ncbi Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses
    Siddhartha Mahanty
    Special Pathogens Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Immunol 170:2797-801. 2003
    ..These data represent the first evidence for a mechanism by which Ebola and Lassa viruses target DC to impair adaptive immunity...
  16. ncbi A serological survey of Ebola virus infection in central African nonhuman primates
    E M Leroy
    Centre International de Recherches Medicales de Franceville, Institut de Recherche pour le Developpement, UR034, Franceville, Gabon
    J Infect Dis 190:1895-9. 2004
    ..They also suggest that future Ebola outbreaks may occur anywhere in the central African forest region...
  17. ncbi Ebola hemorrhagic fever and septic shock
    Mike Bray
    J Infect Dis 188:1613-7. 2003
  18. ncbi The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis
    H Feldmann
    Institut fur Virologie, Philipps Universitat Marburg, Germany
    Arch Virol Suppl 15:159-69. 1999
    ..Whether the soluble glycoproteins GP1 and sGP interfere with the humoral immune response and other defense mechanisms remains to be determined...
  19. pmc Successful topical respiratory tract immunization of primates against Ebola virus
    Alexander Bukreyev
    Laboratory of Infectious Disease, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 8007, USA
    J Virol 81:6379-88. 2007
    ..To our knowledge, this is the first study in which topical immunization through respiratory tract achieved prevention of a viral hemorrhagic fever infection in a primate model...
  20. pmc Ebola virus can be effectively neutralized by antibody produced in natural human infection
    T Maruyama
    Departments of Immunology and Molecular Biology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 73:6024-30. 1999
    ..The neutralizing antibody may be useful in vaccine design and as a prophylactic agent against Ebola virus infection...
  21. ncbi Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice
    T R Gibb
    Diagnostic Systems, United States Army Medical Research Institute of Infectious Diseases (USAMRIID, Fort Detrick, Frederick, Maryland 21702-5011, USA
    J Comp Pathol 125:233-42. 2001
    ..The availability of immunodeficient, "gene-knockout" and transgenic mice will make the mouse model particularly useful for studying the early steps of Ebola pathogenesis...
  22. ncbi An analysis of features of pathogenesis in two animal models of Ebola virus infection
    E I Ryabchikova
    State Research Center of Virology and Biotechnology Vector, Research Institute of Molecular Biology, Koltsovo, Russia
    J Infect Dis 179:S199-202. 1999
    ..The results show that species-specific features of monkeys must be taken into account when choosing an experimental model for studying Ebola virus infection...
  23. pmc Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers
    Kelly L Warfield
    US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland, USA
    PLoS Pathog 2:e1. 2006
    ..The work described here may contribute to development of designer, "druggable" countermeasures for filoviruses and other microbial pathogens...
  24. ncbi Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins
    J A Wilson
    Virology Division, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Frederick, Maryland 21702-5011, USA
    Virology 286:384-90. 2001
    ..The demonstration that the VP proteins are capable of eliciting protective immune responses to EBOV-Z indicates that they may be important components of a vaccine designed to protect humans from Ebola hemorrhagic fever.
  25. doi Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo, 2007
    Eric M Leroy
    Centre International de Recherches Medicales de Franceville CIRMF, Franceville, Gabon
    Vector Borne Zoonotic Dis 9:723-8. 2009
    ..These findings support the suspected role of bats in the natural cycle of Ebola virus and indicate that the massive seasonal fruit bat migrations should be taken into account in operational Ebola risk maps and seasonal alerts in the DRC...
  26. ncbi Ebola outbreak killed 5000 gorillas
    Magdalena Bermejo
    Ecosystèmes Forestiers d Afrique Centrale ECOFAC, Box Postale 15115 Libreville, Gabon
    Science 314:1564. 2006
    ..The lag between neighboring gorilla groups in mortality onset was close to the ZEBOV disease cycle length, evidence that group-to-group transmission has amplified gorilla die-offs...
  27. pmc Wild animal mortality monitoring and human Ebola outbreaks, Gabon and Republic of Congo, 2001-2003
    Pierre Rouquet
    Centre International de Recherches Medicales de Franceville, CIRMF BP 769, Franceville, Gabon
    Emerg Infect Dis 11:283-90. 2005
    ..Wild animal outbreaks began before each of the 5 human Ebola outbreaks. Twice we alerted the health authorities to an imminent risk for human outbreaks, weeks before they occurred...
  28. ncbi Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever
    Steven M Jones
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Canada
    J Infect Dis 196:S404-12. 2007
    ..In the present study, we used the mouse model for Ebola hemorrhagic fever to assess the safety and efficacy of a vaccine based on a live attenuated vesicular stomatitis virus ..
  29. pmc Ebola virus-like particles protect from lethal Ebola virus infection
    Kelly L Warfield
    US Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA
    Proc Natl Acad Sci U S A 100:15889-94. 2003
    ..Together, our data suggest that eVLPs represent a promising vaccine candidate for protection against Ebola virus infections and a much needed tool to examine the genesis and nature of immune responses to Ebola virus...
  30. pmc Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells
    Mangala Rao
    Department of Membrane Biochemistry, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910 7500, USA
    J Virol 76:9176-85. 2002
    ..Although immunization of the monkeys with L(EV)-induced virus-neutralizing antibodies against EBO-Z caused a slight delay in the onset of illness, it did not prevent death...
  31. ncbi Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys
    Thomas W Geisbert
    Virology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA
    Lancet 362:1953-8. 2003
    ..Here, we tested the notion that blockade of fVIIa/tissue factor is beneficial after infection with Ebola virus...
  32. ncbi Human infection due to Ebola virus, subtype Côte d'Ivoire: clinical and biologic presentation
    P Formenty
    World Health Organization and Polyclinique Internationale Sainte Anne Marie, Abidjan, Cote d Ivoire
    J Infect Dis 179:S48-53. 1999
    ..No serologic conversion was detected among contact persons in Côte d'Ivoire (n = 22) or Switzerland (n = 52), suggesting that infection-control precautions were satisfactory...
  33. pmc Ebola hemorrhagic fever transmission and risk factors of contacts, Uganda
    Paolo Francesconi
    Istituto Superiore di Sanita, Rome, Italy
    Emerg Infect Dis 9:1430-7. 2003
    From August 2000 through January 2001, a large epidemic of Ebola hemorrhagic fever occurred in Uganda, with 425 cases and 224 deaths...
  34. ncbi Epitopes involved in antibody-mediated protection from Ebola virus
    J A Wilson
    Virology Division, U S Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Frederick, MD 21702 5011, USA
    Science 287:1664-6. 2000
    ..The identification of protective mAbs has important implications for developing vaccines and therapies for Ebola virus...
  35. ncbi Field investigations of an outbreak of Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: arthropod studies
    P Reiter
    Dengue Branch, Centers for Disease Control and Prevention, San Juan, Puerto Rico 00921 3200, USA
    J Infect Dis 179:S148-54. 1999
    During the final weeks of a 6-month epidemic of Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo, an extensive collection of arthropods was made in an attempt to learn more of the natural history of the disease...
  36. pmc Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs
    Nancy J Sullivan
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    PLoS Med 3:e177. 2006
    ..GP can exert cytopathic effects on transfected cells in vitro, and multiple GP forms have been identified in nature, raising the question of which would be optimal for a human vaccine...
  37. pmc Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses
    Xiangguo Qiu
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS ONE 4:e5547. 2009
    ..Zaire ebolavirus (ZEBOV) produces a lethal viral hemorrhagic fever in humans and non-human primates...
  38. ncbi Human asymptomatic Ebola infection and strong inflammatory response
    E M Leroy
    Centre International de Recherches Medicales de Franceville, Gabon
    Lancet 355:2210-5. 2000
    ..We aimed to determine whether these individuals were indeed infected with Ebola virus, and how they maintained asymptomatic status...
  39. ncbi Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidémies à Kikwit
    S F Dowell
    Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Infect Dis 179:S87-91. 1999
    ..had been infected with Ebola virus were interviewed in order to define the modes of transmission of Ebola hemorrhagic fever (EHF). Of 173 household contacts of the primary cases, 28 (16%) developed EHF...
  40. ncbi Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates
    Peter B Jahrling
    Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, MD, USA
    J Infect Dis 196:S400-3. 2007
    ..These data cast further doubt on the value of passive immunotherapy for the treatment of EBOV infection...
  41. pmc Ebola hemorrhagic fever associated with novel virus strain, Uganda, 2007-2008
    Joseph F Wamala
    Ministry of Heath, Kampala, Uganda
    Emerg Infect Dis 16:1087-92. 2010
    ....
  42. ncbi Interventions to control virus transmission during an outbreak of Ebola hemorrhagic fever: experience from Kikwit, Democratic Republic of the Congo, 1995
    B Kerstiëns
    Medecins Sans Frontieres, Brussels, Belgium
    J Infect Dis 179:S263-7. 1999
    ..was believed to be a concurrent outbreak of bacillary dysentery and viral hemorrhagic fever (suspected Ebola hemorrhagic fever [EHF]) in the town of Kikwit, DRC. On 11 May, the MSF intervention team assessed Kikwit General Hospital...
  43. ncbi Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection
    F Villinger
    Department of Pathology and Laboratory Medicine, School of Medicine, Emory University, Atlanta, Georgia 30322, USA
    J Infect Dis 179:S188-91. 1999
    The role of immune mechanisms in the pathogenesis of Ebola hemorrhagic fever (EHF) remains to be elucidated...
  44. ncbi Catastrophic ape decline in western equatorial Africa
    Peter D Walsh
    Department of Ecology and Evolutionary Biology, Guyot Hall, Princeton, New Jersey 08540, USA
    Nature 422:611-4. 2003
    ..Without aggressive investments in law enforcement, protected area management and Ebola prevention, the next decade will see our closest relatives pushed to the brink of extinction...
  45. ncbi Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever
    Lisa E Hensley
    Virology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA
    J Infect Dis 196:S390-9. 2007
    ..The aim of this study was to test the efficacy of rhAPC as a potential treatment for ZHF...
  46. pmc Early immune responses accompanying human asymptomatic Ebola infections
    E M Leroy
    Centre International de Recherches Medicales de Franceville, BP 769, Franceville, Gabon
    Clin Exp Immunol 124:453-60. 2001
    ..Taken together, these findings improve our understanding about immune response during human asymptomatic Ebola infection, and throw new light on protection against Ebola virus...
  47. pmc Role of natural killer cells in innate protection against lethal ebola virus infection
    Kelly L Warfield
    United States Army Medical Research Institute of Infectious Diseases, 1425 Porter St, Frederick, MD 21702, USA
    J Exp Med 200:169-79. 2004
    ..This work should open new doors for better understanding of Ebola virus pathogenesis and direct the development of immunotherapeutics, which target the innate immune system, for treatment of Ebola virus infection...
  48. ncbi Potential for Ebola transmission between gorilla and chimpanzee social groups
    Peter D Walsh
    Max Planck Institute for Evolutionary Anthropology, Deutscher Platz 6, 04103 Leipzig, Germany
    Am Nat 169:684-9. 2007
    Over the past decade Ebola hemorrhagic fever has emerged repeatedly in Gabon and Congo, causing numerous human outbreaks and massive die-offs of gorillas and chimpanzees. Why Ebola has emerged so explosively remains poorly understood...
  49. pmc Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge
    Alexander Bukreyev
    National Institute of Allergy and Infectious Diseases, Building 50, Room 6505, NIAID, National Institutes of Health, 50 South Dr MSC 8007, Bethesda, MD 20892 8007, USA
    Virology 383:348-61. 2009
    ..Despite the attenuation, the virus was highly immunogenic, and a single IN dose completely protected the animals against a highly lethal intraperitoneal challenge of guinea pig-adapted EBOV...
  50. ncbi A search for Ebola virus in animals in the Democratic Republic of the Congo and Cameroon: ecologic, virologic, and serologic surveys, 1979-1980. Ebola Virus Study Teams
    J G Breman
    Smallpox Eradication Unit, World Health Organization, Geneva, Switzerland
    J Infect Dis 179:S139-47. 1999
    ..30 years after the first outbreak of Marburg virus disease in Germany and Yugoslavia and 20 years after Ebola hemorrhagic fever first occurred in central Africa, the natural history of filoviruses remains unknown...
  51. ncbi Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event
    Thomas W Geisbert
    Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA 21702 5011
    J Infect Dis 188:1618-29. 2003
    ..Thus, chemotherapeutic strategies aimed at controlling overexpression of TF may ameliorate the effects of EBOV hemorrhagic fever...
  52. ncbi Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates
    Nancy J Sullivan
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bldg 40, Room 4502, MSC 3005, 40 Convent Drive, Bethesda, Maryland 20892 3005, USA
    Nature 424:681-4. 2003
    ..This accelerated vaccine provides an intervention that may help to limit the epidemic spread of Ebola, and is applicable to other viruses...
  53. doi Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule
    Nancy J Sullivan
    Biodefense Research Section, Bethesda, Maryland 20892, USA
    Nat Rev Microbiol 7:393-400. 2009
    ..This research provides a basis for bridging the gap from basic research to human vaccine responses in support of the licensing of vaccines through the animal rule...
  54. ncbi Gorilla susceptibility to Ebola virus: the cost of sociality
    Damien Caillaud
    Curr Biol 16:R489-91. 2006
  55. pmc Infection of naive target cells with virus-like particles: implications for the function of ebola virus VP24
    Thomas Hoenen
    Institut fur Virologie, Philipps Universitat Marburg, Marburg, Germany
    J Virol 80:7260-4. 2006
    ..Here we describe a ZEBOV iVLP system which overcomes this limitation and show that VP24 is essential for the formation of a functional ribonucleoprotein complex...
  56. ncbi Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge
    Kelly L Warfield
    US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA
    J Infect Dis 196:S430-7. 2007
    ..We previously had demonstrated the protective efficacy of virus-like particle (VLP)-based vaccines against EBOV and MARV infection in rodents...
  57. ncbi Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995: determinants of survival
    R F Sadek
    Special Pathogens Branch, Centers for Disease Control and Prevention, USA
    J Infect Dis 179:S24-7. 1999
    In May 1995, an international team characterized and contained an outbreak of Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo...
  58. ncbi Spatial and temporal patterns of Zaire ebolavirus antibody prevalence in the possible reservoir bat species
    X Pourrut
    Institut de Recherche pour le Developpement, UR178, Franceville, Gabon
    J Infect Dis 196:S176-83. 2007
    ..monstrosus females suggests virus transmission within bat populations through fighting and sexual contact. Our study, thus, helps to describe Ebola virus circulation in bats and offers some insight into the appearance of outbreaks...
  59. pmc Ecologic and geographic distribution of filovirus disease
    A Townsend Peterson
    Department of Ecology and Evolutionary Biology, University of Kansas, Lawrence, Kansas, USA
    Emerg Infect Dis 10:40-7. 2004
    ..This first large-scale ecologic analysis provides a framework for a more informed search for taxa that could constitute the natural reservoir for this virus family...
  60. ncbi Search for the Ebola virus reservoir in Kikwit, Democratic Republic of the Congo: reflections on a vertebrate collection
    H Leirs
    Danish Pest Infestation Laboratory, Lyngby
    J Infect Dis 179:S155-63. 1999
    ..The epidemiology of Ebola hemorrhagic fever suggests that humans have only intermittent contact with the virus, which complicates selection of target ..
  61. ncbi A novel immunohistochemical assay for the detection of Ebola virus in skin: implications for diagnosis, spread, and surveillance of Ebola hemorrhagic fever. Commission de Lutte contre les Epidémies à Kikwit
    S R Zaki
    Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Infect Dis 179:S36-47. 1999
    Laboratory diagnosis of Ebola hemorrhagic fever (EHF) is currently performed by virus isolation and serology and can be done only in a few high-containment laboratories worldwide...
  62. ncbi Ebola hemorrhagic fever: lessons from Kikwit, Democratic Republic of the Congo
    D L Heymann
    Division of Emerging and Other Communicable Diseases, World Health Organization WHO, Geneva, Switzerland
    J Infect Dis 179:S283-6. 1999
    The outbreak of Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo, clearly signaled an end to the days when physicians and researchers could work in relative obscurity on problems of international importance, and it ..
  63. ncbi Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections
    P B Jahrling
    United States Army Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702 5011, USA
    J Infect Dis 179:S224-34. 1999
    ..Effective treatment of Ebola infections may require a combination of drugs that inhibit viral replication in monocyte/macrophage-like cells while reversing the pathologic effects (e.g., coagulopathy) consequent to this replication...
  64. ncbi Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily
    Lisa E Hensley
    Pathology Division, US Army Medical Research Institute of Infectious Diseases USAMRIID, Attn MCMR UIP D, 1425 Porter Street, Fort Detrick, MD 21702 5011, USA
    Immunol Lett 80:169-79. 2002
    ..Identification of cytokine/chemokine, nitric oxide, and reactive oxygen species involvement in the observed filoviral pathogenesis may lend insight into the rational design of therapeutic countermeasures of filoviral pathogenesis...
  65. ncbi Pathogenesis of filoviral haemorrhagic fevers
    Siddhartha Mahanty
    Malaria Vaccine Development Unit, at the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
    Lancet Infect Dis 4:487-98. 2004
    ..Recent studies in non-human primates have shown that blocking of certain host responses, such as the coagulation cascade, can result in reduced viral replication and improved host survival...
  66. pmc Inflammatory responses in Ebola virus-infected patients
    S Baize
    Centre International de Recherches Medicales de Franceville CIRMF, Franceville, Gabon, France
    Clin Exp Immunol 128:163-8. 2002
    ..In contrast, defective inflammatory responses and massive monocyte/macrophage activation were associated with fatal outcome...
  67. ncbi Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever
    Mike Bray
    Biodefense Clinical Research Branch, Office of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Int J Biochem Cell Biol 37:1560-6. 2005
    b>Ebola hemorrhagic fever is a severe viral infection characterized by fever, shock and coagulation defects...
  68. ncbi Lymphocyte death in a mouse model of Ebola virus infection
    Steven B Bradfute
    Virology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA
    J Infect Dis 196:S296-304. 2007
    ..In a mouse model of ZEBOV infection, lymphocyte death is a prominent finding; however, the mechanism of death and the lymphocyte subsets that are targeted remain unknown...
  69. pmc The temporal program of peripheral blood gene expression in the response of nonhuman primates to Ebola hemorrhagic fever
    Kathleen H Rubins
    Department of Microbiology and Immunology, 299 Campus Dr, Stanford University School of Medicine, Stanford, California 94305, USA
    Genome Biol 8:R174. 2007
    ..Infection with Ebola virus (EBOV) causes a fulminant and often fatal hemorrhagic fever. In order to improve our understanding of EBOV pathogenesis and EBOV-host interactions, we examined the molecular features of EBOV infection in vivo...
  70. ncbi Trigger events: enviroclimatic coupling of Ebola hemorrhagic fever outbreaks
    Jorge E Pinzon
    Biospheric Sciences Branch, Laboratory for Terrestrial Physics, National Aeronautics and Space Administration Goddard Space Flight Center, Greenbelt, MD 20771, USA
    Am J Trop Med Hyg 71:664-74. 2004
    ..data as a correlate of precipitation within tropical Africa and show that the majority of documented Ebola hemorrhagic fever outbreaks were closely associated with sharply drier conditions at the end of the rainy season...
  71. ncbi [Outbreak of Ebola hemorrhagic fever in the Republic of the Congo, 2003: a new strategy?]
    P Formenty
    Département des Maladies transmissibles, Surveillance et Action, Organisation mondiale de la Sante, Geneve, Suisse
    Med Trop (Mars) 63:291-5. 2003
    ..On June 5, the Minister of Health and Population of the Congo Republic officially declared that the outbreak of EHF was over in the Cuvette Ouest Region. The last case was recorded on April 22 in the small village of Ndjoukou...
  72. pmc A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge
    Alexander Bukreyev
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Virol 80:2267-79. 2006
    ....
  73. pmc Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine
    Jason S Richardson
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS ONE 4:e5308. 2009
    ..The immune response elicited by this improved expression cassette vector (Ad-CAGoptZGP) and its ability to afford protection against lethal ZEBOV challenge in mice was compared to the standard Ad-CMVZGP vector...
  74. ncbi Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus
    M Bray
    Virology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID, Fort Detrick, Frederick, Maryland 21702-5011, USA
    J Comp Pathol 125:243-53. 2001
    ..It was noteworthy, however, that mouse-adaptation appeared to have resulted in a degree of attenuation for monkeys...
  75. pmc A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial
    Julie E Martin
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes, Bethesda, MD 20892 3017, USA
    Clin Vaccine Immunol 13:1267-77. 2006
    ....
  76. pmc Recent common ancestry of Ebola Zaire virus found in a bat reservoir
    Roman Biek
    Center for Disease Ecology, Department of Biology, Emory University, Atlanta, Georgia, USA
    PLoS Pathog 2:e90. 2006
  77. pmc Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence
    Graham Simmons
    Department of Microbiology, School of Medicine, University of Pennsylvania, 303A Johnson Pavilion, 3610 Hamilton Walk, Philadelphia, PA 19104 6076, USA
    J Virol 76:2518-28. 2002
    ..A number of other cell surface molecules, however, including major histocompatibility complex class I and the epidermal growth factor receptor, were also down-modulated, suggesting a global mechanism for surface molecule down-regulation...
  78. ncbi Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference
    Thomas W Geisbert
    United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702 5011, USA
    J Infect Dis 193:1650-7. 2006
    ..Here, we describe the development of a potential therapy for EBOV infection that is based on small interfering RNAs (siRNAs)...
  79. ncbi The ecology of Ebola virus
    Allison Groseth
    Special Pathogens Program, National Laboratory for Zoonotic Diseases and Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington St, Winnipeg, MB R3E 3R2, Canada
    Trends Microbiol 15:408-16. 2007
    ....
  80. doi Discovery of swine as a host for the Reston ebolavirus
    Roger W Barrette
    Foreign Animal Disease Diagnostic Laboratory, National Veterinary Services Laboratories, Animal and Plant Health Inspection Services, United States Department of Agriculture, Plum Island Animal Disease Center, New York, NY 11944, USA
    Science 325:204-6. 2009
    ....
  81. pmc Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein
    J A Wilson
    Virology Division, U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702-5011, USA
    J Virol 75:2660-4. 2001
    ..The demonstration that CTLs can prevent lethal Ebola virus infection affects vaccine development in that protective cellular immune responses may be required for optimal protection from Ebola virus...
  82. ncbi Low seroprevalence of IgG antibodies to Ebola virus in an epidemic zone: Ogooué-Ivindo region, Northeastern Gabon, 1997
    Richard T Heffernan
    Department of Epidemiology and Public Health, Division of Epidemiology of Microbial Diseases, Yale University School of Medicine, New Haven, Connecticut, USA
    J Infect Dis 191:964-8. 2005
    ..5%-1.9%). No serum samples were found positive for IgM antibodies to EBO-Z virus. The low seroprevalence suggests that, outside of recognized outbreaks, human exposure to EBO in this epidemic zone is rare...
  83. ncbi Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola hemorrhagic Fever in cynomolgus macaques
    Douglas S Reed
    Center for Aerobiological Sciences, U S Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland, USA
    Viral Immunol 17:390-400. 2004
    ....
  84. ncbi Marburg and Ebola viruses as aerosol threats
    Elizabeth K Leffel
    Center for Aerobiological Sciences, U S Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702 5011, USA
    Biosecur Bioterror 2:186-91. 2004
    ....
  85. ncbi Ebola and Marburg viruses: pathogenesis and development of countermeasures
    Lisa E Hensley
    Virology Division, U S Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, MD 21702 5011, USA
    Curr Mol Med 5:761-72. 2005
    ..In addition, substantial progress has been made in developing recombinant vaccines against these viruses...
  86. pmc Isolates of Zaire ebolavirus from wild apes reveal genetic lineage and recombinants
    Tatiana J Wittmann
    Centre International de Recherches Medicales de Franceville, BP 769 Franceville, Gabon
    Proc Natl Acad Sci U S A 104:17123-7. 2007
    ..The potential for recombination adds an additional level of complexity to unraveling and potentially controlling the emergence of ZEBOV in humans and wildlife species...
  87. ncbi Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with ebola virus secrete MIP-1alpha and TNF-alpha and inhibit poly-IC-induced IFN-alpha in vitro
    M Gupta
    Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Virology 284:20-5. 2001
    ..These data provide the first direct evidence of a role for macrophages in the pathogenesis to Ebola virus and suggest that Ebola virus can inhibit cellular antiviral mechanisms mediated by type I interferons...
  88. ncbi Towards a vaccine against Ebola virus
    Thomas W Geisbert
    Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702 5011, USA
    Expert Rev Vaccines 2:777-89. 2003
    ..This review takes a brief historic look at attempts to develop an efficacious vaccine, provides an overview of current vaccine candidates and highlights strategies that have the greatest potential for commercial development...
  89. ncbi Ebola virus: from discovery to vaccine
    Heinz Feldmann
    Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada
    Nat Rev Immunol 3:677-85. 2003
    ..Further insight into the ecology, immunology and pathogenesis of Ebola virus will promote the delivery of these urgently required tools...
  90. pmc Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections
    Dana L Swenson
    U S Army Medical Research Institute of Infectious Diseases, 1425 Porter St, Fort Detrick, Frederick, Maryland 21702 5011, USA
    Clin Vaccine Immunol 15:460-7. 2008
    ..This study indicates the feasibility of vaccination against all current filovirus threats in the event of natural hemorrhagic fever outbreak or biological attack...
  91. pmc Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells
    Thomas W Geisbert
    United States Army Medical Institute of Infectious Diseases, Fort Detrick, MD 21702 5011, USA
    Am J Pathol 163:2371-82. 2003
    ..Together, these data suggest that coagulation abnormalities associated with EBOV HF are not the direct result of EBOV-induced cytolysis of endothelial cells, and are likely triggered by immune-mediated mechanisms...
  92. pmc Effective post-exposure treatment of Ebola infection
    Heinz Feldmann
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS Pathog 3:e2. 2007
    ....
  93. ncbi A clinical guide to viral haemorrhagic fevers: Ebola, Marburg and Lassa
    Benjamin Jeffs
    Medicens Sans Frontieres, Spain
    Trop Doct 36:1-4. 2006
    ..This article gives a brief overview of diseases caused by the Ebola, Marburg and Lassa viruses. It gives some practical advice to the clinician on the diagnosis and management of these diseases...
  94. ncbi [Ebola and Marburg viruses: the humans strike back]
    Nathalie Alazard-Dany
    Laboratoire des Filovirus, INSERM U758, ENS Lyon, IFR 128 Biosciences Lyon Gerland, Universite Claude Bernard Lyon 1, France
    Med Sci (Paris) 22:405-10. 2006
    ..As for Jones SM et al., they have successfully vaccinated monkeys with recombinant vesicular stomatitis virus expressing Ebola or Marburg virus surface glycoprotein GP, a promising vaccine approach...
  95. ncbi Lessons from nosocomial viral haemorrhagic fever outbreaks
    Susan P Fisher-Hoch
    Department of Epidemiology, University of Texas Houston Health Science Center, School of Public Health, Brownsville Campus, Brownsville, TX, USA
    Br Med Bull 73:123-37. 2005
    ..Educating the public to demand higher standards could be a powerful tool. Good practices are difficult to establish and maintain on the scale needed...
  96. ncbi [Training the trainers seminar and analysis of the Ebola virus hemorrhagic fever outbreaks in central Africa from 2001 to 2004. (Brazzaville, Républic of Congo, April 6-8, 2004]
    P Formenty
    OMS Genève, CDS CSR ARO, Suisse
    Bull Soc Pathol Exot 98:244-54. 2005
  97. ncbi Ebola and great apes in Central Africa: current status and future needs
    W Karesh
    Field Veterinary Program Wildlife Conservation Society, 2300 Southern Blvd, Bronx, NY 10460, USA
    Bull Soc Pathol Exot 98:237-8. 2005
  98. ncbi Medical anthropology and Ebola in Congo: cultural models and humanistic care
    B S Hewlett
    Department of Anthropology, Washington State University, 14204 NE Salmon Creek, Vancouver, WA 98686, USA
    Bull Soc Pathol Exot 98:230-6. 2005
    Seldom have medical anthropologists been involved in efforts to control high mortality diseases such as Ebola hemorrhagic fever (EHF) This paper describes the results of two distinct but complementary interventions during the first ..
  99. ncbi [Multiple Ebola virus haemorrhagic fever outbreaks in Gabon, from October 2001 to April 2002]
    D Nkoghe
    Ministere de la Sante Publique, Libreville, Gabon
    Bull Soc Pathol Exot 98:224-9. 2005
    ..Unexplained deaths of animals had been mentionned in the nearby forests as soon as August 2001: great primates and cephalophus. Samples taken from their carcasses confirmed a concomitant animal epidemic...
  100. ncbi Ebola virus circulation in Africa: a balance between clinical expression and epidemiological silence
    J P Gonzalez
    Institut de recherche pour le developpement IRD, Unité de recherche 178
    Bull Soc Pathol Exot 98:210-7. 2005
    ....
  101. ncbi [Ebola and Marburg fever--outbreaks of viral haemorrhagic fever]
    R Chlibek
    Katedra epidemiologie Fakulty vojenského zdravotnictví Univerzity obrany, Hradec Kralove
    Klin Mikrobiol Infekc Lek 12:217-23. 2006
    ..For this reason, the public should be prepared for possible contact with these highly virulent infections...

Research Grants96

  1. BORNA DISEASE VIRUS AND NEUROPSYCHIATRIC DISEASE
    WALTER LIPKIN; Fiscal Year: 2002
    ..This study will be the first to collect and process human sera and PBMC samples in clinical laboratories with no history of BDV research and dispense aliquots to a central laboratory for randomized, blinded analysis. ..
  2. Initiation of Nucleocapsid Assembly in Ebola virus
    SHARON CRARY; Fiscal Year: 2004
    b>Ebola hemorrhagic fever is among the deadliest of communicable diseases...
  3. Developing small molecule therapeutics for Ebola hemorrhagic fever virus
    Arnab Basu; Fiscal Year: 2010
    ..Identify EBOV inhibitors with in vitro ADME properties suitable for i.v. and oral dosing;and 5. Evaluate EBOV inhibitors in a guinea pig model of EBOV infection. ..
  4. RNA Interference for the Treatment of Ebola and Marburg Hemorrhagic Fever
    Ian MacLachlan; Fiscal Year: 2010
    ....
  5. Neuronal Immunity in HIV Dementia
    HOWARD GENDELMAN; Fiscal Year: 2007
    ..Results of these works should have implications for monitoring disease and in developing novel therapeutics (for example, Alzheimer's disease) which now has few treatment options. ..
  6. HBV Prevention for Homeless At-Risk for HBV/HCV/HIV
    Adeline Nyamathi; Fiscal Year: 2007
    ..abstract_text> ..
  7. Blood Brain Barrier Physiology and HIV Dementia
    HOWARD GENDELMAN; Fiscal Year: 2007
    ..The data acquired could provide new insights and therapeutic intervention strategies for monocyte BBB trafficking during progressive HIV-1 infection in brain tissue. ..
  8. Viral Arrays for Biodefense
    W Ian Lipkin; Fiscal Year: 2007
    ....
  9. RESOURCE FOR NONHUMAN PRIMATE IMMUNE REAGENTS
    Francois Villinger; Fiscal Year: 2007
    ..Preparation, testing and distribution of NHP cytokines/chemokines. 2. Construction and testing of optimized plasmid based constructs for the expression of NHP cytokines/chemokines and immunomodulatory factors. ..
  10. RESOURCE FOR NONHUMAN PRIMATE IMMUNE REAGENTS
    Francois Villinger; Fiscal Year: 2005
    ..3) Development and testing of "primatized" NHP cytokine/chemokines and immunomodulatory factors with extended half-life and biological activity in vivo. ..
  11. A Staged Strategy for Virus Identification and Discovery
    WALTER LIPKIN; Fiscal Year: 2004
    ..Consistent with aims proposed in AI51292, our initial clinical application will be to analyze enteroviral serotypes implicated in human disease in North America. ..
  12. Neuroprotective immunity and HIV dementia
    Howard E Gendelman; Fiscal Year: 2010
    ....
  13. Ebola virus VP24_a novel inhibitor of interferon and oxidative stress signaling
    Christopher F Basler; Fiscal Year: 2011
    ..The experiments in this proposal will clarify the role of two viral proteins, VP24 and VP35, in EBOV disease and suggest new ways to prevent or treat these infections. ..
  14. PD-1 modulation of SIV specific CD4 and CD8 T cell responses
    FRANCOIS J VILLINGER; Fiscal Year: 2011
    ....
  15. Health Promotion Coaching/Vaccine for Homeless Parolees
    Adeline M Nyamathi; Fiscal Year: 2010
    ....
  16. HBV Prevention for Homeless at Risk for HBV/HCV/HIV
    Adeline Nyamathi; Fiscal Year: 2009
    ....
  17. HBV Prevention for Homeless at Risk for HBV/HCV/HIV
    Adeline M Nyamathi; Fiscal Year: 2010
    ....
  18. PD-1 modulation of SIV specific CD4 and CD8 T cell responses
    FRANCOIS J VILLINGER; Fiscal Year: 2010
    ....
  19. Health Promotion Coaching/Vaccine for Homeless Parolees
    Adeline Nyamathi; Fiscal Year: 2009
    ....
  20. HBV Prevention for Homeless at Risk for HBV/HCV/HIV
    Adeline Nyamathi; Fiscal Year: 2009
    ....
  21. RESOURCE FOR NONHUMAN PRIMATE IMMUNE REAGENTS
    Francois Villinger; Fiscal Year: 2009
    ..Preparation, testing and distribution of NHP cytokines/chemokines. 2. Construction and testing of optimized plasmid based constructs for the expression of NHP cytokines/chemokines and immunomodulatory factors. ..
  22. Neuroprotective immunity and HIV dementia
    HOWARD GENDELMAN; Fiscal Year: 2009
    ....
  23. Nanomedicine and NeuroAIDS
    HOWARD GENDELMAN; Fiscal Year: 2009
    ..To address this issue, we plan to develop nanoformulations of commonly used ART with variable brain entry profiles and deliver them directly to diseased brain tissue inside blood-borne macrophages. ..
  24. A DEVELOPMENTAL MODEL FOR AUTISM BASED ON CNS INFECTION
    WALTER LIPKIN; Fiscal Year: 2004
    ..4) Determine how opoptosis contributes to the neuropathology observed after neonatal infection. (5) Analyze regional changes in neurotransmitter systems following neonatal infection. ..
  25. TB/HIV RISK REDUCTION WITH HOMELESS AND DRUG ADDICTED
    Adeline Nyamathi; Fiscal Year: 2002
    ....
  26. HIV-1, MONOCYTES AND THE BLOOD/BRAIN BARRIER
    HOWARD GENDELMAN; Fiscal Year: 2000
    ..The combined efforts are designed to determine the viral and immune determinants for BBB dysfunction in AIDS, information that could be helpful in adapting strategies to prevent migration of monocytes into the brain during HIV dementia. ..
  27. INTERFERON IN MODULATING DENGUE VIRUS INFECTION
    Michael Diamond; Fiscal Year: 2002
    ....
  28. Pathogen Discovery in Chronic Lung Disease by Mass Tag PCR and Microarray
    W Ian Lipkin; Fiscal Year: 2007
    ....
  29. Mass Tag PCR Detection of Respiratory Pathogens
    W Ian Lipkin; Fiscal Year: 2004
    ..abstract_text> ..
  30. Monoclonal Antibody Therapy for West Nile Virus
    Michael Diamond; Fiscal Year: 2007
    ..These studies are an essential first step in the generation of humanized mAbs that have utility as therapeutic agents against WNV in humans. ..
  31. MOLECULAR MECHANISMS OF HIV NEUROPATHOGENESIS
    HOWARD GENDELMAN; Fiscal Year: 2002
    ....
  32. HBV Prevention for Homeless At-Risk for HBV/HCV/HIV
    Adeline Nyamathi; Fiscal Year: 2004
    ....
  33. EBOLA VIRUS INTERFERON-ANTAGONISTS AND VIRULENCE
    CHRISTOPHER BASLER; Fiscal Year: 2003
    ..VP35 and VP24 may also prove to be attractive targets for new antiviral agents. Inhibition of anti-IFN factors may sensitize Ebola virus infected cells to the antiviral effects of IFN and may also enhance the effect of antiviral agents. ..
  34. MOLECULAR ANALYSIS OF A NEUROTROPIC AGENT--BORNA VIRUS
    WALTER LIPKIN; Fiscal Year: 2002
    ....
  35. Training Program in Neurovirology
    HOWARD GENDELMAN; Fiscal Year: 2006
    ....
  36. Development of Novel Antiviral Agents VS West Nile Virus
    Michael Diamond; Fiscal Year: 2006
    ....
  37. Alcohol Use Reduction in Methadone Individuals with HCV
    Adeline Nyamathi; Fiscal Year: 2007
    ....
  38. CD4 Immune Reconstitution in SIV Infection
    Francois Villinger; Fiscal Year: 2007
    ..Results of these studies will form the basis for future immune reconstitution strategies in human HIV infected patients. ..
  39. Antibody-Based Protection Against Dengue Virus
    Michael Diamond; Fiscal Year: 2007
    ..In Specific Aim 4, we will develop epitope-based diagnostic assays and immunogens for DENV. Collectively, these studies may be of significant importance in ongoing and future DENV vaccine development programs. ..
  40. Community-Based Approach to Designing an AIDS Program for HIV+ Mothers in India
    Adeline Nyamathi; Fiscal Year: 2007
    ..These findings will lead to future funding to actually develop and test a newly designed program. ..
  41. MODELING THE UNDERSTANDING OF CHILDHOOD ASTHMA
    Adrian Casillas; Fiscal Year: 2002
    ..The candidate will have access to equipment, supplies, and technical support from the sponsor's laboratory. ..